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SUMMARY
Oxidative stress, through the production of reactive oxygen
species (ROS), has been proposed as the root cause under-
lying the development of insulin resistance, b-cell dysfunc-
tion, impaired glucose tolerance and type 2 diabetes
mellitus (T2DM). It has also been implicated in the pro-
gression of long-term diabetes complications, including
microvascular and macrovascular dysfunction. Excess nour-
ishment and a sedentary lifestyle leads to glucose and fatty
acid overload, resulting in production of ROS.
Additionally, reaction of glucose with plasma proteins
forms advanced glycation end products, triggering
production of ROS. These ROS initiate a chain reaction
leading to reduced nitric oxide availability, increased mar-
kers of inflammation and chemical modification of lipo-
proteins, all of which may increase the risk of
atherogenesis. With the postulation that hyperglycaemia
and fluctuations in blood glucose lead to generation of
ROS, it follows that aggressive treatment of fasting and
postprandial hyperglycaemia is important for prevention of
micro and macrovascular complications in T2DM.
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INTRODUCTION
Worldwide, there were approximately 194 million adults aged
20–79 years with diagnosed diabetes mellitus (DM) in 2003
(with type 2 diabetes accounting for 90–95% of all diagnosed
cases), and that number is expected to increase to 333 million
over the next 20 years (1). Diabetes is associated with
increased coronary artery, cerebrovascular and peripheral vas-
cular disease, with up to 80% of deaths in people with
diabetes caused by cardiovascular disease (1). Diabetes is
also largely responsible for blindness, amputations and end
stage renal disease in the developed world (1). Because of this,
it is important to recognise and treat this devastating disease
early in its progression to postpone or even prevent the serious
complications associated with it.
A currently favoured hypothesis is that oxidative stress,
through a single unifying mechanism of superoxide produc-
tion, is the common pathogenic factor leading to insulin
resistance, b-cell dysfunction, impaired glucose tolerance
(IGT) and ultimately to type 2 DM (T2DM) (2).
Furthermore, this mechanism has been implicated as the
underlying cause of both the macrovascular and microvascular
complications associated with T2DM (3). It follows that
therapies aimed at reducing oxidative stress would benefit
patients with T2DM and those at risk for developing
diabetes.
To optimise the treatment of these patients, it is necessary
to understand the root cause of oxidative stress. Excess nour-
ishment, combined with a sedentary lifestyle, results in over-
abundance of glucose and fatty acid accumulation within
muscle, adipose tissue and pancreatic cells. This leads to the
generation of excess reactive oxygen species (ROS), particu-
larly superoxide anion, through the mitochondrial electron-
transport chain (3,4). Recently, it has been suggested that fluc-
tuating blood glucose concentrations, like those observed
during postprandial glycaemic excursions in people with IGT
or T2DM, may contribute significantly to oxidative stress –
perhaps even more so than chronically elevated blood glucose
(5,6).
This review will focus on the factors leading to the gen-
eration of ROS in diabetes and the effects of oxidative stress
on vascular function and cardiac risk factors. Additionally,
practical considerations for earlier identification and treat-
ment of persons at risk for developing T2DM will be
discussed.
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CONTROL IN MINIMISING OXIDATIVE STRESS
Achieving Target HbA1c Values may not be Sufficient
Evidence now exists to suggest that maintaining tight blood
glucose control, by reducing the frequency and magnitude of
glucose excursions, may be as important to the reduction in
long-term complications of diabetes as achieving a target
HbA1c value (5,6). Attaining HbA1c values <7% has gener-
ally been considered a benchmark of successful diabetes ther-
apy. It is important to note, however, that while HbA1c values
have been accepted as biomarkers for glycaemic control, they
represent an average measure of glycaemic exposure over time.
Because of this, individuals who have identical HbA1c values
may have experienced widely varying blood glucose ranges
over the period of time reflected by the HbA1c value.
Results from a subgroup analysis 2 years after the completion
of the Diabetes Complications and Control Trial (DCCT)
demonstrated in patients with type 1 diabetes that, despite having
similar HbA1clevels, participants in the intensive treatment group
showed a marked reduction in the risk of development of diabetic
retinopathy compared with their counterparts in the conventional
treatment group (7). Some have hypothesised that there was a
greater frequency and magnitude of glycaemic excursions in the
conventionally treated patients compared with patients in the
intensive treatment group, and that this increased glycaemic
variability generated more ROS, leading to vascular damage (5).
Variable Glucose: Effects on Markers of Oxidative Stress
and Inflammation
Several in vitro studies have demonstrated increased expres-
sion of markers of oxidative stress in cells exposed to fluctuat-
ing glucose concentrations (8–10). One such study examined
the effects of variable glucose concentrations vs. constant high
or normal glucose conditions on cultured human umbilical
vein endothelial cells (8). The investigators monitored the
generation of ROS by measuring levels of nitrotyrosine and
showed higher levels of nitrotyrosine in cells exposed to vari-
able glucose concentrations than for cells exposed to either
constant normal or elevated glucose concentrations (8).
Owing to the ability to monitor ROS production via mea-
surement of nitrotyrosine, there are now data in patients with
T2DM that make evident the existence of increased oxidative
stress in response to postprandial hyperglycaemia (11). In a
study comparing T2DM patients with matched healthy con-
trols, nitrotyrosine levels were significantly higher in diabetic
individuals in the fasting state and were further elevated in the
postprandial state. No such postprandial elevation in nitrotyr-
osine was observed in healthy control patients (11).
Markers of inflammation, a well-recognised manifestation
of oxidative stress, have also been observed to increase in
response to intermittent elevated glucose levels (10). In a study
comparing the effects of inconsistent vs. constant glycaemic
conditions on cultured human kidney cells, the authors noted
that production of the inflammatory cytokines, transforming
growth factor b (TGF-b) and insulin-like growth factor binding
protein (IGFBP)-3, increased to a greater extent when exposed
to variable glucose concentrations compared with constant
hyperglycaemic conditions. The authors concluded that while
maintenance of normal blood glucose levels would result in the
smallest degree of oxidative stress and inflammation in the
tubulointerstitium, variable glycaemic control would likely be
even more damaging than constant hyperglycaemia (10).
EFFECTS OF OXIDATIVE STRESS ON VASCULAR
FUNCTION AND CARDIAC RISK FACTORS
The adverse effects of oxidative stress on the cardiovascular system
are numerous and varied but may be generally categorised into
effectsonnitricoxideavailability,inflammatoryresponseandlipid
and lipoprotein modifications.(Figure1, asummary oftheeffects
of hyperglycaemia and oxidative stress on vascular function.)
Reduction of Nitric Oxide Availability
Paradoxically, hyperglycaemic conditions result simultaneously
in both increased NO production anddecreasedNOavailability
(12–16). However, reduction in NO availability is the primary
pathogenic factor that appears responsible for endothelial dys-
function and diabetic angiopathy (12). The molecular mechan-
isms behind this apparent paradox are as follows: superoxide
anions, resulting from hyperglycaemia, activate nuclear factor-
kB( N F - kB), which causes increased expression of inducible
nitric oxide synthase (iNOS) (16). This increase in iNOS results
in amplified generation of NO. However, when superoxide
anions are present at high concentration, they rapidly react
with the newly created NO to form the strong oxidant perox-
ynitrite (15). The net result is an overall decline in the avail-
ability of NO to the endothelium and the formation of
peroxynitrite, which is itself toxic to endothelial cells.
Peroxynitrite exerts its toxiceffect through oxidation of proteins,
initiation of lipid peroxidation and nitration of amino acids
(15). Another consequence of hyperglycaemia-induced produc-
tion of superoxide anions is the inhibition of endothelial NOS,
reducing thegenerationofNOandcontributingtotheuniversal
NO deficiency (14). The ultimate outcome of this reduction in
NO availability is defective endothelial-dependent vasodilation,
leading to microvascular and macrovascular complications.
Increased Markers of Inflammation – Implications for
Accelerated Atherosclerosis
Cytokines. Inflammation is involved in the pathogenesis of
every stage of atherosclerosis (17,18). It has been proposed
that T2DM is a disease of the immune system, involving a
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In T2DM, there is an accelerated rate of atherosclerosis,
which is thought to be due, in part, to the irreversible forma-
tion and deposition of molecules known as advanced glyca-
tion end products (AGEs) (20). Elevated blood glucose levels
contribute to the glycation of proteins and lipids, resulting in
the formation of AGEs (20).
Receptors for AGEs (RAGE) are expressed in many differ-
ent tissues and cell types, including endothelial cells, vascular
smooth muscle cells and macrophages (21–23). The binding
of AGEs to RAGE leads to the intracellular generation of
ROS (24,25), which, in turn, activate NF-kB. As a conse-
quence of NF-kB activation, expression of a variety of
cytokines is increased, including tumour necrosis factors
(TNF-a and TNF-b), interleukins (IL) 1, 6, 8 and 18 and
interferon-g (26,27).
A recent clinical study suggests that acute hyperglycaemia
can result in elevated levels of circulating inflammatory cyto-
kines, in particular TNF-a, IL-6 and IL-18 (27). The study
demonstrated that increased cytokine levels were more pro-
nounced in response to intermittent plasma glucose spikes
compared with constant hyperglycaemia. These results were
observed in both nondiabetic patients and patients with IGT.
However, cytokine elevations were greater and lasted longer
in patients with IGT compared with nondiabetic patients.
Moreover, administration of glutathione (a powerful
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Figure 1 Glucose in the plasma undergoes non-enzymatic reaction with circulating proteins (including lipoproteins) to form AGEs.
AGEs bind with RAGE on the surface of endothelial cells lining blood vessels, triggering the production of ROS, in particular super oxide
anion, by NADPH oxidase. ROS are also produced as a result of glucose overload within the mitochondria. Once formed, ROS activate NFkB,
which results in the transcriptional activation of genes relevant for inflammation, immunity and atherosclerosis. AGE, advanced glycation/
glycoxidation endproduct; RAGE, receptor for AGE; ROS, reactive oxygen species; O2
–, super oxide anion; NADPH, nicotinamide adenine
dinucleotide phosphate (reduced form); NFkB, nuclear factor kB; TNF-a, tumour necrosis factor a; IL, interlukin; PAI-1, plasminogen
activator inhibitor 1; ICAM-1, intercellular adhesion molecule 1; VCAM-1, vascular cell adhesion molecule; NO, nitric oxide.
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cytokine elevation in response to intermittent glucose pulses,
supporting the concept that an oxidative stress mechanism med-
iates the inflammatory effect of hyperglycaemia in humans (27).
Acute-phase reactants. One of the many sequelae to the
generation of ROS is cytokine-induced stimulation of acute-
phase reactant synthesis by the liver (28). Cytokines – pri-
marily TNF-a and IL-6 – stimulate the synthesis of C-reac-
tive protein, complement, serum amyloid A and fibrinogen,
to name a few (29). Other examples of acute-phase reactants
that are known to be elevated in T2DM include plasminogen
activator inhibitor 1 (PAI-1), von Willebrand factor, lipopro-
tein(a) and cortisol (29).
Cellular adhesion molecules. Another adverse effect of hyper-
glycaemia-induced oxidative stress on vascular function is
increased expression of cellular adhesion molecules on the
endothelial cell surface (30). These molecules attach to circulating
leucocytes, leading to the formation of the atherosclerotic plaque.
Plasma from diabetic individuals contains elevated levels of
some soluble forms of these cellular adhesion molecules,
specifically intercellular adhesion molecule (ICAM)-1, vascu-
lar cell adhesion molecule (VCAM)-1 and E-selectin (31).
Although the exact mechanism is unclear, recent data strongly
suggest that, in humans, postprandial hyperglycaemia and
hypertriglyceridemia generate increased expression of cellular
adhesion molecules through a pathway mediated by oxidative
stress (30). Specifically, nitrotyrosine levels fluctuate in con-
cert with plasma ICAM-1, VCAM-1 and E-selectin concen-
trations in response to consumption of high fat and/or
glucose. Furthermore, short-term treatment with simvastatin,
a drug proposed to have intracellular antioxidant properties,
reduced postprandial plasma concentrations of nitrotyrosine,
as well as ICAM-1, VCAM-1 and E-selectin (30). It should
be noted that it is currently unknown whether this is a
property observed across all medications in this class, or
specific only to certain statins. Thus, postprandial acute eleva-
tions in plasma glucose and lipids, and the ensuing generation
of ROS, likely result in amplified circulating levels of cellular
adhesion molecules, increasing the risk of atherogenesis.
Modification of Lipoproteins and Lipids – Contributions
to Atherosclerosis
Lipoprotein glycation and glycoxidation. In addition to the
primary dislipidemia of T2DM, chemical modifications to
lipoproteins [e.g., low-density lipoprotein (LDL) and high-
density lipoprotein (HDL)] may contribute to diabetic cardi-
ovascular complications. One such modification, glycation/
glycoxidation of lipoprotein, has been observed early in the
progression of diabetes and has been shown to be correlated
with other measures of glycaemia such as HbA1c (32,33).
Glycated and glycoxidised lipoproteins are formed through
a non-enzymatic process in which sugars bind to free amino
groups of the lipoprotein (34,35). These compounds undergo
further rearrangement to yield irreversible AGE structures.
Lipoprotein modification takes place in the absence (glyca-
tion) and presence (glycoxidation) of oxygen (36). These
chemical modifications can alter lipoprotein structure and
function (37). For example, pro-atherogenic properties have
been observed for glycated/glycoxidised-LDL (33,38).
Additionally, glycated/glycoxidised-LDL has been shown to
increase PAI-1 production and decrease tissue plasminogen
activator in cultured human vascular endothelial cells, sugges-
tive of a prothrombotic effect (39).
Lipid peroxidation and lipoxidation. Although the two
terms appear similar, lipid peroxidation and lipoxidation are
two distinct processes. Recent evidence suggests a central role
for both of these chemical reactions in the development of
cardiovascular disease in diabetes (40).
Lipid peroxidation is the formation of lipid peroxides via
enzymatic and/or non-enzymatic mechanisms. ROS resulting
from hyperglycaemia are thought to contribute to the initiation
of lipidperoxidation (41).Once formed, lipidperoxidesundergo
a series of complex reactions, ultimately binding chemically to
proteinsandyieldingadvancedlipoxidationendproducts(ALEs)
(42–44). Thus, lipoxidation is the covalent binding of products
of lipid peroxidation reactions to proteins (36).
Studies of oxidised lipoproteins and vascular cells have
demonstrated numerous pro-atherogenic effects of oxidised
LDL and ALE-containing LDL. These include, but are not
limited to, increased smooth muscle cell proliferation, increased
apoptosis in endothelial cells, induction of macrophage-derived
foam cell formation, activation of protein kinase-C and trans-
forming growth factor-beta (TGF-b), increased matrix produc-
tion, increased endothelin-1, decreased nitric oxide bio-
availability, pro-inflammatory effects, pro-clotting effects and
inhibition of antioxidant enzymes (37).
That many of the effects on vascular endothelial cells caused
byALE-containinglipoproteinsaresimilar tothoseobservedfor
AGE–RAGE interactions may be explained by the fact that
several AGEs and ALEs share common reactive intermediates,
formed during glycoxidation or lipid peroxidation reactions,
respectively (45). For this reason, it has been suggested that
the chronic excess of substrate (whether lipid or carbohydrate)
present inT2DM results increation ofan abundance of reactive
intermediates, leading to increased chemical modification of
proteins (AGEs and ALEs) and persistentsaturation of receptors
such as RAGE, contributing to the atherogenic process (36).
PRACTICAL CONSIDERATIONS FOR THE
CLINICIAN
Early Diagnosis and Intervention
The results from the DCCT and Epidemiology of Diabetes
Interventions and Complications (EDIC) studies highlight
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prevention of long-term complications. For patients at high
risk for development of T2DM, performance of an oral
glucose tolerance test is important for detection of an impair-
ment in early phase insulin release, a condition which is
always present in type 2 diabetic patients, and occurs early
in the development of the disease (46). Unfortunately,
depending solely on fasting blood glucose measurement for
the diagnosis of diabetes may miss individuals who have
isolated postprandial hyperglycaemia but a normal fasting
plasma glucose (47). Prospective studies have shown that
this abnormality is not only common but it doubles the
mortality risk (47,48).
Patients diagnosed with T2DM require close monitoring
and intensified therapy when appropriate. It has been demon-
strated that nonfasting plasma glucose is a better indicator of
overall glycaemic control than fasting glucose in these patients
(49), and an recent study established the utility of casual
postprandial glucose measurements in determining the appro-
priate time for intensified therapy (50). Casual postprandial
plasma glucose (cPPG) was defined simply as the plasma
glucose concentration determined 1–4 h after consumption
of a meal, regardless of the meal size or composition (50). A
cutoff cPPG value of >150 mg/dL had a positive predictive
value of 88% for an HbA1c level >6.5% (50). While acquisi-
tion of an HbA1c level is still recommended for a thorough
analysis, the 150 mg/dL cutoff for cPPG can provide a con-
venient indicator of the need for intensified therapy in type 2
diabetic patients when home blood glucose monitoring
records or current HbA1c levels are not available (50).
Pharmacological Therapy
Effective treatment of patients with T2DM requires the com-
bination of diet, exercise, oral agents, incretin hormones and
insulin and should be aimed at maintaining blood glucose
levels as close to normal as possible, while minimising blood
glucose fluctuations and hypoglycaemia. There are five classes
of oral agents currently available: sulphonylureas; biguanides
(metformin); a-glucosidase inhibitors (acarbose, miglitol);
thiazolidinediones (pioglitazone, rosiglitazone); and megliti-
nides (nateglinide, repaglinide). With the exception of the
a-glucosidase inhibitors and the meglitinides, the majority
of the oral antihyperglycaemic agents act by lowering fasting
plasma glucose levels via increased insulin secretion or
increased insulin sensitivity (51). The meglitinides are rapid-
acting insulin secretagogues and are therefore targeted to
control postprandial glucose excursions. Similarly, a-glucosi-
dase inhibitors lower postprandial glucose spikes by inhibiting
the enzymatic break down of carbohydrates in the small
intestine, thereby slowing carbohydrate absorption and blunt-
ing the increase in plasma glucose. Reviews of oral agent
therapy, treatment algorithms and guidelines for dosing
have previously been published (51–53).
Because T2DM is a disease characterised by the progressive
loss of pancreatic b-cell function, most patients will even-
tually require insulin replacement therapy (54).
Unfortunately, clinicians often wait too long to initiate insu-
lin therapy, resulting in excessive glycaemic exposure that may
go unchecked for months or even years (55). The guidelines
for glycaemic control published by the American Diabetes
Association (ADA) and American College of Endocrinology
(ACE) are helpful in determining which patients should be
started on insulin. The goals for glycaemic control recom-
mended by ADA include an HbA1c level <7%, a fasting
plasma glucose (FPG) concentration of 90–130 mg/dL, and
a peak postprandial plasma glucose (PPG)(1–2 h after meal)
concentration <180 mg/dL (56). The comparable values
from ACE are an HbA1c ¼ 6.5%, a FPG concentration
<110 mg/dL and a 2-h PPG concentration <140 mg/dL
(57).
The ideal insulin regimen is the basal-bolus regimen (long-
or intermediate-acting basal insulin in combination with
rapid-acting insulin analogues at each meal), because it closely
mimics the normal physiologic insulin profile. However,
basal-bolus therapy requires a great deal of motivation on
the part of both the patient and the physician and necessitates
thorough training in food/insulin matching and insulin
adjustment (58). This level of complexity has led to the
widespread use of therapies based only on basal insulin
which, although simple to initiate, only treat the fasting
blood glucose and fail to correct the postprandial blood
glucose excursions and which, as described above, may lead
to increased oxidative stress. Therefore, insulin therapies
aimed at improving blood glucose should target both post-
prandial and fasting glycaemia. A twice-daily regimen using a
premixed preparation of rapid-acting insulin analogs is a good
alternative for patients who are reluctant to start a basal-bolus
regimen initially (58). A comprehensive, yet practical guide to
determining the most appropriate time for initiating insulin
therapy and the most effective insulin regimen was recently
published by Hirsch et al. (58).
CONCLUSIONS
Poorly controlled blood glucose levels can lead to numerous
pathological conditions that ultimately result in long-term
microvascular and macrovascular complications. It is now
understood that a mechanism underlying hyperglycaemia-
induced effects on inflammation and vascular dysfunction is
the action of ROS within the cell nucleus. This action initi-
ates a cascade of transcription events, ultimately leading to
changes in the levels of NO, cytokines, acute-phase reactants
and cellular adhesion molecules. Generation of ROS can be
reduced by avoiding hyperglycaemia and by minimising
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these fluctuations in blood glucose is postprandial glycaemia.
Furthermore, the earlier in the progression of T2DM that
tight control of blood glucose can be achieved, the greater will
be the reduction in long-term complications. Therefore, we
propose that it is of utmost importance to diagnose patients at
risk for developing T2DM as early as possible and to aggres-
sively treat those already diagnosed by appropriately treating
both fasting and postprandial glycaemia.
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